|
BMS-247550 Plus Capecitabine in Treating Patients With Metastatic Breast Cancer Clinical Trials Information presented on Clinical Trials Search isn't intended to be a substitute for proven healthcare advice, trips or treatment using a real physician. We are not docs. Always confer with your mD on BMS-247550 Plus Capecitabine in Treating Patients With Metastatic Breast Cancer conditions. Clinical Trials Search.org is a site dedicated to listing clinical research studies in human subjects. BMS-247550 Plus Capecitabine in Treating Patients With Metastatic Breast Cancer Clinical research trials and BMS-247550 Plus Capecitabine in Treating Patients With Metastatic Breast Cancer medical trials take place in hundreds of localities across the U.S.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually measure the effectiveness of new drugs. The intention of the studies / projects is to resolve certain human health questions. Clinical trials are a popular means for physicians, government agencies, and private sector corporations to detect remedies for all forms of circumstances, like BMS-247550 Plus Capecitabine in Treating Patients With Metastatic Breast Cancer. BMS-247550 Plus Capecitabine in Treating Patients With Metastatic Breast Cancer Clinical Trials and other clinical trials allow for volunteers to undergo healthcare treatment options before they are available to the masses. Most times the participants receive treatment for free, and every now and again they are paid for their time. Occasionally there is a cost for a BMS-247550 Plus Capecitabine in Treating Patients With Metastatic Breast Cancer clinical trial. Subjects typically recieve the finest healthcare available for their BMS-247550 Plus Capecitabine in Treating Patients With Metastatic Breast Cancer condition. Hazards are a reality, nonetheless, and might include more or frequent mD trips, health risks (potentially life-endangering), and/or the treatment being ineffective. Trials are federally regulated with stern guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "B" Clinical Trials Conditions > BMS-247550 Plus Capecitabine in Treating Patients With Metastatic Breast Cancer  BMS-247550 Plus Capecitabine in Treating Patients With Metastatic Breast Cancer
BMS-247550 Plus Capecitabine in Treating Patients With Metastatic Breast Cancer
For Condition: stage 4 breast cancer,recurrent breast cancer
Status: No longer recruiting
Sponsor(s): Jonsson Comprehensive Cancer Center , National Cancer Institute (NCI)
Synopsis: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of combining BMS-247550 with capecitabine in treating patients who have metastatic breast cancer that has not responded to previous chemotherapy.
Details: OBJECTIVES: - Determine the maximum tolerated dose of BMS-247550 and capecitabine, on 2 different schedules, in patients with metastatic breast cancer previously treated with a taxane and an anthracycline. - Determine the safety profile of this regimen in these patients. - Determine, preliminarily, any antitumor activity of this regimen in these patients. OUTLINE: This is a dose-escalation study. Patients are assigned to 1 of 2 groups. - Group I: Patients receive BMS-247550 IV over 3 hours on day 1 and oral capecitabine twice daily on days 1-14. - Group II: Patients receive BMS-247550 IV over 1 hour on days 1-3 and capecitabine as in group I. Treatment in both groups repeats every 3 weeks for 2-18 courses in the absence of disease progression or unacceptable toxicity. Cohorts of 6 patients receive escalating doses of BMS-247550 and capecitabine until the maximum tolerated dose (MTD) is determined for each group. The MTD is defined as the dose at which no more than 1 of 6 patients experiences dose-limiting toxicity. Additional patients are treated at the MTD. Patients are followed for at least 30 days and then every 3 months thereafter. PROJECTED ACCRUAL: Approximately 34-60 patients will be accrued for this study within 8-12 months.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: DISEASE CHARACTERISTICS: - Histologically or cytologically confirmed breast cancer - Metastatic disease by radiography or histology - Must have received prior chemotherapy with a taxane and an anthracycline in the adjuvant or metastatic setting - No more than 2 prior chemotherapy regimens in the metastatic setting - Measurable or evaluable disease - Bone lesions not measurable - Primary breast lesions not measurable if assessed only by physical exam - No active brain metastasis - No cerebral edema by CT scan or MRI - No progression since prior imaging studies - No requirement for steroids - No clinical symptoms of brain metastasis - Hormone receptor status: - Not specified PATIENT CHARACTERISTICS: Age - 18 and over Sex - Not specified Menopausal status - Not specified Performance status - ECOG 0-1 Life expectancy - At least 3 months Hematopoietic - Absolute neutrophil count at least 2,000/mm^3 - Platelet count at least 100,000/mm^3 - Hemoglobin at least 9.0 g/dL Hepatic - Bilirubin no greater than 1.5 times upper limit of normal (ULN) - ALT no greater than 2.5 times ULN Renal - Creatinine less than 1.5 times ULN Cardiovascular - No uncontrolled or significant cardiovascular disease - No myocardial infarction within the past year - No uncontrolled angina within the past year - No history of congestive heart failure - No history of atrial or ventricular arrhythmias - No history of second- or third-degree heart block - No uncontrolled hypertension Other - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception - HIV negative - No hypersensitivity to Cremophor EL or fluorouracil - No prior intolerance to fluoropyrimidines - No other serious uncontrolled medical disorder or active infection that would preclude study - No dementia or altered mental status that would preclude study - No grade 2 or greater neuropathy (neuromotor or neurosensory) PRIOR CONCURRENT THERAPY: Biologic therapy - See Chemotherapy - Prior immunotherapy allowed - No concurrent trastuzumab (Herceptin) - No concurrent immunotherapy Chemotherapy - See Disease Characteristics - At least 3 weeks since prior chemotherapy (6 weeks for nitrosoureas, mitomycin, or doxorubicin HCl liposome) - At least 2 years since prior high-dose chemotherapy with bone marrow transplantation or peripheral blood stem cell support - No prior epothilone, capecitabine, or continuous-infusion fluorouracil - No other concurrent chemotherapy Endocrine therapy - Prior hormonal therapy allowed - No concurrent hormonal therapy - Concurrent hormone replacement therapy allowed Radiotherapy - At least 3 weeks since prior radiotherapy - No prior radiotherapy to more than 25% of the bone marrow - No concurrent therapeutic radiotherapy Surgery - Not specified Other - At least 3 weeks since prior investigational cytotoxic agents - No concurrent warfarin for therapeutic anticoagulation - Low-dose warfarin allowed for implanted ports or indwelling catheters - No other concurrent experimental anticancer medications - No other concurrent antitumor therapy - Concurrent bisphosphonates for palliation of bone metastases allowed if initiated before study
Total Enrollment:
Location and Contact Information:
Overall Study Official:
LinneaChap, Study Chair, Jonsson Comprehensive Cancer Center
Jonsson Comprehensive Cancer Center, UCLA
Los Angeles, California, 90095-1781
United States
Additional Information:
Study ID Numbers: CDR0000258052; UCLA-0206011,BMS-CA163-031,NCI-G02-2120
Study Start Date:
Record last reviewed: February 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00049244
Other Recurrent Breast Cancer Studies:
1. Radiolabeled SMT-487 in Treating Patients With Refractory Small Cell Lung Cancer or Metastatic Breast Cancer
2. Shark Cartilage in Treating Patients With Advanced Colorectal or Breast Cancer
3. Peripheral Stem Cell Transplantation in Treating Patients With Melanoma or Small Cell Lung, Breast, Testicular, or Kidney Cancer That is Metastatic or That Cannot Be Treated With Surgery
4. Combination Chemotherapy in Treating Patients With Metastatic Breast Cancer
5. Gefitinib With or Without Tamoxifen in Treating Patients With Tamoxifen-Resistant Metastatic Breast Cancer
Related Studies:
Other recurrent breast cancer Clinical Trials
Other California Clinical Trials
Other Los Angeles Clinical Trials
BMS-247550 Plus Capecitabine in Treating Patients With Metastatic Breast Cancer
|
|
|
|
|
|
|
|
